• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Unum Therapeutics appoints Jörn Aldag to board of directors

Unum Therapeutics appoints Jörn Aldag to board of directors

February 10, 2016
CenterWatch Staff

Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, has appointed Jörn Aldag to its board of directors. Aldag brings over two decades of experience leading innovative biotech companies.

“Jörn is one of the true pioneers in building companies that bring novel and potentially curative therapies to patients with severe conditions, and we are very excited to have him join our board,” said Chuck Wilson, Ph.D., president and CEO of Unum Therapeutics. “With his experience, I expect Jörn to provide invaluable insights to our team as we continue to build Unum, seek to bring our Antibody-Coupled T-cell Receptor (ACTR) therapy to patients, and work to change the way cancer is treated.”

Aldag currently is the chairman of Molecular Partners, Zurich, Switzerland—a company developing a new class of small protein therapies called DARPins. Until recently, he was the chief executive officer of the gene therapy company uniQure, the first company to ever receive approval of a gene therapy product from a Western regulatory agency.

“As cellular immunotherapies emerge as one of the most promising approaches in oncology, Unum’s leadership team and ACTR technology position the company for success,” said Aldag. “I am looking forward to working with the board and Unum’s management during the next phase of the company’s growth.”

Before his tenure at uniQure, Aldag was president and CEO of Evotec, a company focused on small molecule drug discovery. There he successfully developed a pipeline of CNS programs and drove the acquisitions of LSE-listed Oxford Asymmetry and NASDAQ-listed Renovis.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing